RBC Capital Markets Adjusts Price Target for Design Therapeutics
RBC Capital Markets maintained its 'Outperform' rating on Design Therapeutics while lowering its price target from $20 to $19.
Stocks · News reference
Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
RBC Capital Markets maintained its 'Outperform' rating on Design Therapeutics while lowering its price target from $20 to $19.
Design Therapeutics announced its financial results for the third quarter of 2026, reporting a net loss of $20.3 million and providing updates on its clinical-stage GeneTAC pipeline.
U.S. stock futures mostly lower, Nasdaq 100 down 0.3%. Marvell Technology shares fall 7.6% after beating estimates, other stocks also drop in pre-market.